Enteric HTC is an NIHR (National Institute for Health Research) funded initiative with a remit to facilitate the development of innovative medical technology in the area of gastrointestinal (GI) medicine. We work with companies of all sizes to assist in taking products from proof of concept to a regulatory approved, market ready product. Whether you are a start-up/spin out company, an SME or a large multinational, Enteric HTC can offer a range of services:

  • Technology evaluation and clinical applications – we are a patient focussed, clinician led organisation with access to GI key opinion leaders able to advise on new technologies and their clinical focus.
  • Access to clinical networks – if you are looking to trial a device, our clinical network may be useful in finding recruitment sites and advising on trial design.
  • Funding applications – we are available to advise on appropriate funding streams to apply for and to review applications prior to submission.
  • Access to patient groups - if you wish to organise meetings or conduct Patient and Public Involvement (PPI), we can facilitate these activities via our partnered charity Bowel and Cancer Research (B&CR).
  • Regulatory advice – we offer guidance on a range of regulatory barriers including classification, clinical investigations and the CE marking process.

We work with companies by producing a Technology Development Partnership (TDP) between Enteric HTC and interested parties This is an agreement to collaborate on developing new technology to meet unmet clinical needs. If you have a new idea or wish to discuss a project with us, we will sign a non-disclosure agreement (NDA) prior to initial discussions.

Currently, our focus is on four main themes within GI medicine:

  • Stoma (e.g. innovations that reduce the need for a stoma, prevent stoma complications or improve current appliances and quality of life for ostomates)
  • Treatments at the neural interface (e.g. implantable or transcutaneous therapies that effect neuromodulation, including electroceuticals)
  • Novel diagnostics (in-vivo or in-vitro technologies, e.g. intraluminal or cross-sectional imaging, physiological measurement devices, and laboratory assays)
  • Safe and effective surgery (e.g. surgical instruments and implants, intra-operative imaging and lighting, and other theatre environmental innovations)

Please note, Enteric HTC’s remit does not include pharmaceutical research, or the commercialisation of new technologies once developed.